Bronchodilator Drugs - Israel | Statista Market Forecast

The Bronchodilator Drugs market in Israel is expected to witness a significant growth in the coming years.
By 2024, the projected revenue in this market is estimated to reach US$86.73m.
This growth is expected to continue with an annual growth rate of 3.69% from 2024 to 2029, resulting in a market volume of US$104.00m by 2029.
When compared globally, it is noteworthy that United States is anticipated to generate the highest revenue in the Bronchodilator Drugs market, with a projected revenue of US$17.34bn in 2024.
Israel has seen a steady increase in the demand for bronchodilator drugs, driven by a growing aging population and high rates of respiratory diseases.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. In Israel, the market for bronchodilator drugs has been witnessing steady growth in recent years.

Customer preferences: Patients in Israel prefer bronchodilator drugs that provide quick relief from respiratory symptoms. They also prefer drugs that have minimal side effects and are easy to use. As a result, there is a high demand for inhalers and nebulizers in the Israeli market.

Trends in the market: The Israeli bronchodilator drugs market is expected to grow in the coming years due to the increasing prevalence of respiratory diseases in the country. The aging population is also a key driver of the market, as older people are more susceptible to respiratory diseases. Additionally, the growing awareness about the benefits of early diagnosis and treatment of respiratory diseases is expected to boost the demand for bronchodilator drugs in Israel.

Local special circumstances: Israel has a well-developed healthcare system, which provides universal coverage to its citizens. The country has a high rate of healthcare expenditure, which is expected to further increase in the coming years. This is likely to drive the demand for bronchodilator drugs in the country, as patients will have greater access to healthcare services.

Underlying macroeconomic factors: Israel has a strong economy with a high GDP per capita. The country has a highly educated workforce and a thriving technology sector. These factors are expected to drive the growth of the bronchodilator drugs market in Israel, as patients will have greater purchasing power and access to advanced healthcare technologies. Additionally, the government has been investing heavily in the healthcare sector, which is expected to further boost the market for bronchodilator drugs in Israel.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.